A proteomic approach to understanding the development of multidrug-resistant Candida albicans strains

H. Kusch, K. Biswas, S. Schwanfelder, S. Engelmann, Phillip Rogers, M. Hecker, J. Morschhäuser

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Resistance of the pathogenic yeast Candida albicans to the antifungal agent fluconazole is often caused by the overexpression of genes that encode multidrug efflux pumps (CDR1, CDR2, or MDR1). We have undertaken a proteomic approach to gain further insight into the regulatory network controlling efflux pump expression and drug resistance in C. albicans. Three pairs of matched fluconazole-susceptible and resistant clinical C. albicans isolates, in which drug resistance correlated with stable activation of MDR1 or CDR1/2, were analyzed for differences in their protein expression profiles. In two independent, MDR1-overexpressing, strains, additional up-regulated proteins were identified, which are encoded by the YPR127 gene and several members of the IFD (YPL088) gene family. All are putative aldo-keto reductases of unknown function. These proteins were not up-regulated in a fluconazole-resistant strain that overexpressed CDR1 and CDR2 but not MDR1, indicating that expression of the various efflux pumps of C. albicans is controlled by different regulatory networks. To investigate the possible role of YPR127 in the resistance phenotype of the clinical isolates, we constitutively overexpressed the gene in a C. albicans laboratory strain. In addition, the gene was deleted in a C. albicans laboratory strain and in one of the drug-resistant clinical isolates in which it was overexpressed. Neither forced overexpression nor deletion of YPR127 affected the susceptibility of the strains to drugs and other toxic substances, suggesting that the regulatory networks which control the expression of efflux pumps in C. albicans also control genes involved in cellular functions not related to drug resistance.

Original languageEnglish (US)
Pages (from-to)554-565
Number of pages12
JournalMolecular Genetics and Genomics
Volume271
Issue number5
DOIs
StatePublished - Jun 1 2004

Fingerprint

Candida albicans
Proteomics
Fluconazole
Drug Resistance
Genes
MDR Genes
Proteins
Antifungal Agents
Poisons
Pharmaceutical Preparations
Yeasts
Phenotype

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Genetics

Cite this

A proteomic approach to understanding the development of multidrug-resistant Candida albicans strains. / Kusch, H.; Biswas, K.; Schwanfelder, S.; Engelmann, S.; Rogers, Phillip; Hecker, M.; Morschhäuser, J.

In: Molecular Genetics and Genomics, Vol. 271, No. 5, 01.06.2004, p. 554-565.

Research output: Contribution to journalArticle

Kusch, H, Biswas, K, Schwanfelder, S, Engelmann, S, Rogers, P, Hecker, M & Morschhäuser, J 2004, 'A proteomic approach to understanding the development of multidrug-resistant Candida albicans strains', Molecular Genetics and Genomics, vol. 271, no. 5, pp. 554-565. https://doi.org/10.1007/s00438-004-0984-x
Kusch, H. ; Biswas, K. ; Schwanfelder, S. ; Engelmann, S. ; Rogers, Phillip ; Hecker, M. ; Morschhäuser, J. / A proteomic approach to understanding the development of multidrug-resistant Candida albicans strains. In: Molecular Genetics and Genomics. 2004 ; Vol. 271, No. 5. pp. 554-565.
@article{4fccfe551d48467fb12c8b33d4c7e30e,
title = "A proteomic approach to understanding the development of multidrug-resistant Candida albicans strains",
abstract = "Resistance of the pathogenic yeast Candida albicans to the antifungal agent fluconazole is often caused by the overexpression of genes that encode multidrug efflux pumps (CDR1, CDR2, or MDR1). We have undertaken a proteomic approach to gain further insight into the regulatory network controlling efflux pump expression and drug resistance in C. albicans. Three pairs of matched fluconazole-susceptible and resistant clinical C. albicans isolates, in which drug resistance correlated with stable activation of MDR1 or CDR1/2, were analyzed for differences in their protein expression profiles. In two independent, MDR1-overexpressing, strains, additional up-regulated proteins were identified, which are encoded by the YPR127 gene and several members of the IFD (YPL088) gene family. All are putative aldo-keto reductases of unknown function. These proteins were not up-regulated in a fluconazole-resistant strain that overexpressed CDR1 and CDR2 but not MDR1, indicating that expression of the various efflux pumps of C. albicans is controlled by different regulatory networks. To investigate the possible role of YPR127 in the resistance phenotype of the clinical isolates, we constitutively overexpressed the gene in a C. albicans laboratory strain. In addition, the gene was deleted in a C. albicans laboratory strain and in one of the drug-resistant clinical isolates in which it was overexpressed. Neither forced overexpression nor deletion of YPR127 affected the susceptibility of the strains to drugs and other toxic substances, suggesting that the regulatory networks which control the expression of efflux pumps in C. albicans also control genes involved in cellular functions not related to drug resistance.",
author = "H. Kusch and K. Biswas and S. Schwanfelder and S. Engelmann and Phillip Rogers and M. Hecker and J. Morschh{\"a}user",
year = "2004",
month = "6",
day = "1",
doi = "10.1007/s00438-004-0984-x",
language = "English (US)",
volume = "271",
pages = "554--565",
journal = "Molecular Genetics and Genomics",
issn = "1617-4615",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - A proteomic approach to understanding the development of multidrug-resistant Candida albicans strains

AU - Kusch, H.

AU - Biswas, K.

AU - Schwanfelder, S.

AU - Engelmann, S.

AU - Rogers, Phillip

AU - Hecker, M.

AU - Morschhäuser, J.

PY - 2004/6/1

Y1 - 2004/6/1

N2 - Resistance of the pathogenic yeast Candida albicans to the antifungal agent fluconazole is often caused by the overexpression of genes that encode multidrug efflux pumps (CDR1, CDR2, or MDR1). We have undertaken a proteomic approach to gain further insight into the regulatory network controlling efflux pump expression and drug resistance in C. albicans. Three pairs of matched fluconazole-susceptible and resistant clinical C. albicans isolates, in which drug resistance correlated with stable activation of MDR1 or CDR1/2, were analyzed for differences in their protein expression profiles. In two independent, MDR1-overexpressing, strains, additional up-regulated proteins were identified, which are encoded by the YPR127 gene and several members of the IFD (YPL088) gene family. All are putative aldo-keto reductases of unknown function. These proteins were not up-regulated in a fluconazole-resistant strain that overexpressed CDR1 and CDR2 but not MDR1, indicating that expression of the various efflux pumps of C. albicans is controlled by different regulatory networks. To investigate the possible role of YPR127 in the resistance phenotype of the clinical isolates, we constitutively overexpressed the gene in a C. albicans laboratory strain. In addition, the gene was deleted in a C. albicans laboratory strain and in one of the drug-resistant clinical isolates in which it was overexpressed. Neither forced overexpression nor deletion of YPR127 affected the susceptibility of the strains to drugs and other toxic substances, suggesting that the regulatory networks which control the expression of efflux pumps in C. albicans also control genes involved in cellular functions not related to drug resistance.

AB - Resistance of the pathogenic yeast Candida albicans to the antifungal agent fluconazole is often caused by the overexpression of genes that encode multidrug efflux pumps (CDR1, CDR2, or MDR1). We have undertaken a proteomic approach to gain further insight into the regulatory network controlling efflux pump expression and drug resistance in C. albicans. Three pairs of matched fluconazole-susceptible and resistant clinical C. albicans isolates, in which drug resistance correlated with stable activation of MDR1 or CDR1/2, were analyzed for differences in their protein expression profiles. In two independent, MDR1-overexpressing, strains, additional up-regulated proteins were identified, which are encoded by the YPR127 gene and several members of the IFD (YPL088) gene family. All are putative aldo-keto reductases of unknown function. These proteins were not up-regulated in a fluconazole-resistant strain that overexpressed CDR1 and CDR2 but not MDR1, indicating that expression of the various efflux pumps of C. albicans is controlled by different regulatory networks. To investigate the possible role of YPR127 in the resistance phenotype of the clinical isolates, we constitutively overexpressed the gene in a C. albicans laboratory strain. In addition, the gene was deleted in a C. albicans laboratory strain and in one of the drug-resistant clinical isolates in which it was overexpressed. Neither forced overexpression nor deletion of YPR127 affected the susceptibility of the strains to drugs and other toxic substances, suggesting that the regulatory networks which control the expression of efflux pumps in C. albicans also control genes involved in cellular functions not related to drug resistance.

UR - http://www.scopus.com/inward/record.url?scp=3142672919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142672919&partnerID=8YFLogxK

U2 - 10.1007/s00438-004-0984-x

DO - 10.1007/s00438-004-0984-x

M3 - Article

VL - 271

SP - 554

EP - 565

JO - Molecular Genetics and Genomics

JF - Molecular Genetics and Genomics

SN - 1617-4615

IS - 5

ER -